How to beat rogue antibodies at their own game [Sponsored]

Summary

Science Quickly – "How to Beat Rogue Antibodies at Their Own Game"

Hosted by: Scientific American
Aired: July 30, 2026
Featured Guest: Karen Massey, CEO of Argenex
Host: Aline Augenbraun

---

Episode Overview

This episode explores the challenges and breakthroughs in treating autoimmune diseases, where the body's immune system turns against itself. The conversation with Karen Massey, the new CEO of Argenex—a pioneering immunology company—dives into how targeted drug therapies are evolving, specifically those that can identify and "remove" harmful antibodies from the body. The discussion focuses on scientific innovation, patient-centered research processes, and the road from discovery to treatment.

---

Key Discussion Points & Insights

The Argonaut Spirit and Argenex’s Mission

• Teamwork & Innovation:
  Massey likens Argenex’s team to mythical Argonauts—a group undertaking audacious tasks through collaboration.

  "The story of the Argonauts is all about a team of people working together to achieve the unthinkable... by working together as a team, having this big, bold ambition, even when it seems impossible..." — Karen Massey [00:55]

• Leadership Philosophy:
  Massey emphasizes her role as a CEO embedded within the team, fostering curiosity and courage to challenge norms.

  "I'm in the boat with all of those Argonauts and I'm rolling up my sleeves and doing as much as I can to push out innovation..." — Karen Massey [01:28]

---

Understanding Autoimmune Diseases and IgG

• Basics of Autoimmune Disease:
  Host explains that autoimmune diseases arise when the immune system’s IgG antibodies mistakenly attack healthy tissue.

  "When Iggs form to attack normal tissue, you get an autoimmune disease." — Aline Augenbraun [02:13]

• Therapeutic Focus:
  Argenex's approach is novel in looking beyond just the IgG molecule to the network of interactions that regulate it.

  "You're looking at Iggs and the whole system that interacts with ig." — Aline Augenbraun [02:32]

---

FCRN: Turning the Body’s Systems Against Rogue Antibodies

• Mechanism Explained:
  The team is focused on exploiting FCRN (neonatal Fc receptor), a “transport system” for IgG molecules, to selectively remove harmful antibodies.

  "FCRN is sort of a transportation system. What we do is we, let's say, hijack that FCRN system to be able to pull autoantibodies across... disposed of so they can't do harm." — Karen Massey [03:51]

• Drug Engineering:
  The process is described as hijacking a cellular “trash disposal” system. Argenex's drugs guide faulty IgGs for destruction, preventing them from causing harm.

  "Instead of picking up an autoimmune IgG from the outside of the cell and spitting it out unharmed, Argenex's drug guides the rogue igg to the cell's garbage compactor, the lysosome. For destruction." — Aline Augenbraun [04:12]

---

The Path from Discovery to Patients

• Collaborative Innovation:
  Argenex embraces an open, collaborative approach with external experts, clinicians, and patients to refine both the scientific target and practical delivery.

  "We don't assume that just our scientists have all the answers... they're out engaging with other scientists... what we call co-creating..." — Karen Massey [04:48]

• Clinical Process:
  Massey highlights that developing a new therapy is an intricate process involving safety studies, clinical collaboration, and meaningful patient involvement in trial design. The journey from idea to treatment can take a decade or more.

  "From the inception of an idea to the patient, getting the medicine can be a decade..." — Karen Massey [05:43]

---

Deciding What to Pursue

• Selection Criteria:
  Projects are chosen based on a rigorous evaluation: scientific rationale, feasibility, regulatory factors, and—crucially—unmet patient need.

  "We have to meet that third criteria [unmet patient need] in order to move forward." — Karen Massey [05:59]

---

What Excites the CEO

• Biggest Excitement:
  Massey beams about ongoing discoveries that involve targeting fundamental immune pathways, which could treat multiple diseases with precise interventions.

  "Our scientists continue to identify and uncover these new insights... look at these places where we can intervene that are very targeted... you can impact many different diseases." — Karen Massey [06:35]

---

Notable Quotes & Memorable Moments

• The Argonauts Analogy

  "If we work together, we'll be able to deliver that mission for patients." — Karen Massey [01:07]

• Drug as a Trash Disposal System

  "Argenex turned an anti FCRN into a drug to speed up trash disposal." — Aline Augenbraun [04:12]

• Timelines & Patient Voice

  "Many, many, many years. From the inception of an idea to the patient, getting the medicine can be a decade, depending on how novel the biology is..." — Karen Massey [05:43]

---

Timestamps for Important Segments

• Argonaut Spirit and Leadership: [00:55] – [02:02]
• Autoimmune Disease and IgG Mechanisms: [02:02] – [03:00]
• Targeting FCRN, Drug’s Mechanism: [03:00] – [04:34]
• From Idea to Patient: Discovery and Clinical Trials: [04:34] – [05:43]
• Research Selection Process: [05:43] – [06:30]
• Most Exciting Science: [06:30] – [07:08]

---

Conclusion

This episode offers an insider view into the science and strategy behind new therapies for autoimmune diseases, highlighting the importance of collaboration, rigorous process, and staying focused on patient needs. Argenex aims to turn the body’s own machinery against rogue antibodies, providing hope for more precise and effective treatments for those affected by these conditions.

---

For more bite-size science, stay tuned to Science Quickly by Scientific American.

Transcript

[A]

Almost all of us know someone who suffers from an autoimmune disease. Or maybe you do yourself. Autoimmune diseases are common. Only cancer and cardiovascular diseases are more prevalent. So how do you fight a body that is fighting against itself? Argenyx, an immunology innovation company that develops antibody based therapies, is developing a new toolkit of molecules that can tamp down the rebelling part of the immune system. Scientific American Custom Media recently talked to Argenex's new CEO, Karen Massey, about what's in the toolkit and how it's helping patients. Karen Massey, thank you so much for joining us. I've heard that you and your colleagues call yourselves Argonauts. Can you explain why you folks call yourselves that and what you bring to the table as the lead Argonaut?

[B]

Yeah, absolutely. The story of the Argonauts actually is what inspired our co founders of Argenics to call our company Argenics and therefore we call ourselves Argonauts. It's a. The story of the Argonauts is all about a team of people working together to achieve the unthinkable. So we see our mission as bringing transformative medicines to patients. And we believe the only way that we can do that is by working together as a team, having this big, bold ambition even when it seems impossible, that if we work together, we'll be able to deliver that mission for patients. And from my perspective, as I step into this, this new role as CEO of the company, I'm in the boat with all of those Argonauts and I'm rolling up my sleeves and doing as much as I can to push out innovation in our thinking, to make sure we're staying curious, make sure that we're staying courageous and thinking big, challenging the status quo and really uncovering new cool science, new biology that can deliver transformative outcomes for patients.

[A]

I know Argenex's expertise is the immune system. We've all got this army of immune proteins within us that fight off invaders. For example, immunoglobulin G or IgG plays a role in protecting the body from bacteria, viruses and cancer. But when Iggs form to attack normal tissue, you get an autoimmune disease. I know argenexx is developing some new therapies to treat autoimmune diseases. One thing I find really fascinating about your approach is that you're looking at Iggs and the whole system that interacts with ig. Drug toolkit.

[B]

Yeah, absolutely. So I'm not a scientist myself and I find it Fascinating. When I learn all the intricacies of how the immune system works, it's incredibly complicated.

[A]

Indeed it is. Yet you, as the head of the company, have to be sure your scientists have the resources and guidance they need. What are you focusing on right now?

[B]

What we're working on is figuring out what are really targeted and precise ways that we can correct when the system goes awry, leveraging components of the immune system to help us to do that. And so certainly with fcrn, what it allows us to do is use the part of the immune system that removes these autoantibodies from the body using the kind of natural removal system that the body has.

[A]

FCRN stands for Neonatal FC Receptor. Normally, FCRN binds to an IgG molecule and protects it from being destroyed. That makes sense if you want to keep IgG proteins around to fight infections or cancer. But if you want to get rid of iggs that are attacking the body itself, then you probably want to block fcrn, right?

[B]

Yeah. So FCRN is sort of a transportation system. What we do is we, let's say, hijack that FCRN system to be able to pull autoantibodies across, go into, let's say, the, the trash removal system so that those autoantibodies that are causing the trouble, that's the immune system gone awry, they get pulled across and disposed of so they can't do harm.

[A]

I like that. A trash disposal service, Argenex, turned an anti FCRN into a drug to speed up trash disposal. Instead of picking up an autoimmune IgG from the outside of the cell and spitting it out unharmed, Argenex's drug guides the rogue igg to the cell's garbage compactor, the lysosome. The. For destruction.

[B]

Exactly.

[A]

Can you guide us down the path a discovery takes from an idea in someone's head to a therapy that's actually used by everyday people. How does Argenex get there?

[B]

Yeah, I think this is one of the coolest parts of our industry, but in particular how we do it at Argenics, we don't assume that just our scientists have all the answers or know all of the solutions to these problems. They're out engaging with other scientists and really what we call co creating, taking it from. Hey, we've identified this target that we might want to look at to how do we create a molecule that can either block or activate or sweep or do whatever we think needs to be done, Actually physically build that molecule in the lab, and then we continue to collaborate to bring it to patients. So once it's gone through safety studies. Then we collaborate with clinicians who are treating these patients. How should we design the clinical trial? How do we make sure that we're proving efficacy or safety on the most important parameters? We get patient input so that we make sure that we're focused on what's most important to patients.

[A]

And how long does that process take? Typically?

[B]

Many, many, many years. From the inception of an idea to the patient, getting the medicine can be a decade, depending on how novel the biology is, how complicated it is, and what the pathway is.

[A]

How do you pick what research projects to invest in?

[B]

Yeah, first of all, I would say all of our programs are aimed at addressing unmet needs. We use a really rigorous process for selecting which indications we want to target. Do we understand the biology? And is there a biology rationale? Can we develop this molecule in this indication? Are there endpoints? Is there a regulatory pathway? But really importantly, is there an unmet patient need? We have to meet that third criteria in order to move forward.

[A]

Of everything that Argenex is working on, what are you most excited about right now?

[B]

Well, we are working on a lot, and it's always hard to choose the favorite because there's so much exciting science that's ongoing. Certainly, from my perspective, what I'm most excited about is how our scientists continue to identify and uncover these new insights. Really look at the foundational components of the immune system and of our immune response, and look at these places where we can intervene that are very targeted, but at the same time, by targeting them, you can impact many different diseases. So that's what I find most exciting.

[A]

Thank you for joining us. Karen Massey is the CEO of Argenex, a company committed to helping improve the lives of people with rare autoimmune diseases. This podcast was produced by Scientific American Custom Media and made possible through the support of Argenics. Thank you for listening. For Scientific American Custom Media, I'm Aline Augenbraun.